Keynote 2: Challenges in conducting TCM Randomized Control Clinical Trials for Infectious Diseases

​

Keynote 2: Challenges in conducting TCM Randomized Control Clinical Trials for Infectious Diseases

Date: 6 July 2025, Sunday | Time: 1300 - 1330 | Venue: The NAK Auditorium, Academia 

Co-Chairs: Dr Siau Chuin (CGH)

Speaker: Dr (TCM) Huang Tse-Hung (黃澤宏)

RespireAid™ (NRICM101) has been licensed as a drug or dietary supplement to target infection, virus replication, and cytokine storms. A total of 260 participants were and enrolled at two medical centers in Taiwan. Compared with the placebo control group, There were statistically significant differences between RespireAidTM and the placebo control groups in duration of sore throat alleviation (p=0.001), the ratios of symptom resolution (p=0.019), and the use of rescue medication (p=0.022). There was no statistically significant difference in the proportion of adverse events between the two groups after treatment. Clinical trial registration：ID, NCT06086093,Evaluate the Efficacy of RespireAidTM in Patient With Externally Contracted Seasonal Epidemic (外感時疫) Taiwan's government authorities use Western medicine models to manage Chinese medicine, putting Chinese medicine clinical trials in a difficult situation.